RecruitingNCT06204406

Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy

Studying Upper tract urothelial carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
RenJi Hospital
Intervention
Observational(other)
Enrollment
106 target
Eligibility
18-90 years · All sexes
Timeline
2023 – 2028

Study locations (1)

Collaborators

Shanghai Zhongshan Hospital · Tianjin Medical University Second Hospital · Xiangya Hospital of Central South University · West China Hospital · Ruijin Hospital · First Affiliated Hospital Xi'an Jiaotong University · The First Affiliated Hospital of University of Science and Technology of China · The Second Hospital of Anhui Medical University · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06204406 on ClinicalTrials.gov

Other trials for Upper tract urothelial carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Upper tract urothelial carcinoma →

← Back to all trials